This trial is conducted in Europe. The aim of this trial is to to investigate if there is a drug-drug interaction between liraglutide and paracetamol (Benuron®) and to investigate the effect of liraglutide on post prandial glucose.

Inclusion Criteria:

• Type 2 diabetes mellitus
• Diet-treated subjects with type 2 diabetes with HbA1c 7.5-9.5 %
• Subjects with type 2 diabetes in oral anti-diabetic drug (OAD) monotherapy treated with metformin or alpha-glucosidase inhibitors with HbA1c 7.0-9.5%
• Body mass index (BMI) 18.5-40 kg/m^2
• Subjects should have a stable body weight for at least 3 months prior to screening (as judged by the Investigator)

Exclusion Criteria:

• Impaired liver function
• Impaired renal function
• Clinically significant active cardiovascular disease including history of myocardial infarction within the last 6 months and/or heart failure
• Any clinically significant abnormal ECG (electrocardiogram)
• Uncontrolled treated/untreated hypertension
• Recurrent severe hypoglycaemia as judged by the Investigator
• Active hepatitis B and/or active hepatitis C
• Positive human immunodeficiency virus (HIV) antibodies
• Known or suspected allergy to trial product(s) or related products